Several health-care stocks moved higher on Canadian, European and U.S. regulatory action Thursday, and one of the biggest moves came from Dendreon(DNDN Quote), which recently was climbing 33%.
The Food and Drug Administration confirmed it would accept either a positive interim or final analysis of survival from Dendreon's latest trial to approve its prostate-cancer vaccine Provenge. Shares were up $2.48 to $9.23.
Avanir Pharmaceuticals(AVNR Quote) got the FDA's approval to market a new orally disintegrating tablet formulation of its antipsychotic drug clozapine, marketed as FazaClo. Previously the drug was available in 25-mg and 100-mg dosage strengths in blister packaging, but the company will now additionally market bottle packaging and a 12.5-mg dosage strength. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet